Abstract
BackgroundTreatment with biotechnological agents (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol) in ankylosing spondylitis (AS) is effective. However, evidence regarding the potential efficacy of these anti-TNF drugs in the extra-articular...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
